Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | SHBG | P04278 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14445220 | 0.83 | ALDH1A1 (0.56) | ALDH1A1NPSR1TSHRL3MBTL1THRB | |
| SCHEMBL11671119 | 0.82 | SHBG (0.42) | ALDH1A1NPSR1TSHRSHBGL3MBTL1 | |
| SCHEMBL1877913 | 0.81 | ALDH1A1 (0.54) | ALDH1A1NPSR1TSHRL3MBTL1THRB | |
| SCHEMBL1879048 | 0.78 | ALDH1A1 (0.50) | ALDH1A1NPSR1TSHRL3MBTL1THRB | |
| SCHEMBL8330052 | 0.70 | TSHR (0.43) | ALDH1A1NPSR1TSHRSHBGL3MBTL1 | |
| SCHEMBL7606538 | 0.69 | CYP2C19 (0.43) | ALDH1A1NPSR1HTTGAA | |
| SCHEMBL16586202 | 0.69 | CYP2C19 (0.43) | ALDH1A1NPSR1HTTGAA | |
| SCHEMBL7767118 | 0.69 | CA12 (0.34) | — | |
| SCHEMBL8330062 | 0.68 | TSHR (0.48) | ALDH1A1NPSR1TSHRL3MBTL1THRB | |
| SCHEMBL873716 | 0.68 | ALDH1A1 (0.47) | ALDH1A1NPSR1TSHRSHBGL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7868022-B2 | 2-amino-quinoline derivatives useful as inhibitors of β-secretase (BACE) | JANSSEN PHARMACEUTICA NV (BE) | 2011-01-11 | — | — | US | disclosed |
| US-7776882-B2 | 2-amino-3,4-dihydro-quinoline derivatives useful as inhibitors of β-secretase (BACE) | JANSSEN PHARMACEUTICA NV (BE) | 2010-08-17 | — | — | US | disclosed |
| US-20080194624-A1 | 2-AMINO-QUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) | JANSSEN PHARMACEUTICA NV (BE) | 2008-08-14 | — | — | US | disclosed |
| US-20070232642-A1 | 2-AMINO-3,4-DIHYDRO-QUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) | JANSSEN PHARMACEUTICA NV (BE) | 2007-10-04 | — | — | US | disclosed |
| WO-2007092846-A2 | 2-AMINO-3,4-DIHYDRO-QUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF β-SECRETASE (BACE) | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-08-16 | — | — | WO | disclosed |
| WO-2007092854-A2 | 2-AMINO-QUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF β-SECRETASE (BACE) | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194624-A1 | 2-AMINO-QUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) | BACE2, BACE1, PSEN2 | ALDH1A1 3765/4885NPSR1 2109/4885TSHR 4876/4885 |
| US-20070232642-A1 | 2-AMINO-3,4-DIHYDRO-QUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) | BACE2, PSEN2, BACE1 | ALDH1A1 3248/4885NPSR1 1967/4885TSHR 4880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.